Stifel lowered the firm’s price target on Sight Sciences (SGHT) to $4 from $5 and keeps a Buy rating on the shares. 2025 revenue guidance of $70M-$75M fell short of the firm’s latest $75M estimate, though the firm is “inclined to believe conservatism is factored into guidance,” the analyst tells investors in an earnings recap note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences: Hold Rating Amid Revenue Challenges and Reimbursement Progress
- Sight Sciences price target lowered to $3.50 from $5.50 at Piper Sandler
- Sight Sciences Faces Headwinds in Glaucoma and Dry Eye Markets, Hold Rating Maintained
- Sight Sciences Reports 2024 Results and 2025 Outlook
- Sight Sciences sees FY25 revenue $70M-$75M, consensus $78.07M